These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 25512810)
1. Medical and dietary therapy for kidney stone prevention. Gul Z; Monga M Korean J Urol; 2014 Dec; 55(12):775-9. PubMed ID: 25512810 [TBL] [Abstract][Full Text] [Related]
2. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. Pak CY; Heller HJ; Pearle MS; Odvina CV; Poindexter JR; Peterson RD J Urol; 2003 Feb; 169(2):465-9. PubMed ID: 12544288 [TBL] [Abstract][Full Text] [Related]
4. [Randomized trials in the prevention of recurrent calcium oxalate stones]. Presne C; Monge M; Bataille P; el Esper N; Choukroun G; Fournier A Nephrologie; 2003; 24(6):303-7. PubMed ID: 14584297 [TBL] [Abstract][Full Text] [Related]
5. Prevention of stone disease. Porena M; Guiggi P; Micheli C Urol Int; 2007; 79 Suppl 1():37-46. PubMed ID: 17726351 [TBL] [Abstract][Full Text] [Related]
6. Prophylaxis of uric acid and cystine stones. Hess B Urol Res; 1990; 18 Suppl 1():S41-4. PubMed ID: 2291249 [TBL] [Abstract][Full Text] [Related]
7. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Sterrett SP; Penniston KL; Wolf JS; Nakada SY Urology; 2008 Aug; 72(2):278-81. PubMed ID: 18533229 [TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. Pearle MS; Roehrborn CG; Pak CY J Endourol; 1999 Nov; 13(9):679-85. PubMed ID: 10608521 [TBL] [Abstract][Full Text] [Related]
9. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy. Pak CY; Sakhaee K; Fuller CJ Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957 [TBL] [Abstract][Full Text] [Related]
10. Kidney stones: pathophysiology and medical management. Moe OW Lancet; 2006 Jan; 367(9507):333-44. PubMed ID: 16443041 [TBL] [Abstract][Full Text] [Related]
11. Prevention of nephrolithiasis. Pearle MS Curr Opin Nephrol Hypertens; 2001 Mar; 10(2):203-9. PubMed ID: 11224695 [TBL] [Abstract][Full Text] [Related]
12. The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers. Favus MJ; Coe FL Scand J Urol Nephrol Suppl; 1980; 53():265-71. PubMed ID: 6938003 [TBL] [Abstract][Full Text] [Related]
13. Prevention of recurrent calcium stones: diet versus drugs. Jaeger P Miner Electrolyte Metab; 1994; 20(6):410-3. PubMed ID: 7783704 [TBL] [Abstract][Full Text] [Related]
14. Medical management of nephrolithiasis. Pak CY J Urol; 1982 Dec; 128(6):1157-64. PubMed ID: 6759686 [No Abstract] [Full Text] [Related]
15. Medical dissolution therapy for the treatment of uric acid nephrolithiasis. Gridley CM; Sourial MW; Lehman A; Knudsen BE World J Urol; 2019 Nov; 37(11):2509-2515. PubMed ID: 30810833 [TBL] [Abstract][Full Text] [Related]
16. Hypocitraturia as a pathogenic risk factor in the mixed (calcium oxalate/uric acid) renal stones. Alvarez Arroyo MV; Traba ML; Rapado A Urol Int; 1992; 48(3):342-6. PubMed ID: 1589930 [TBL] [Abstract][Full Text] [Related]
17. [Two cases of uric acid stones unsuccessfully dissociated by oral chemolysis]. Funahashi M; Yamada T; Murayama T Hinyokika Kiyo; 2006 Jan; 52(1):47-8. PubMed ID: 16479990 [TBL] [Abstract][Full Text] [Related]
18. Update on dietary recommendations and medical treatment of renal stone disease. Heilberg IP Nephrol Dial Transplant; 2000 Jan; 15(1):117-23. PubMed ID: 10607782 [No Abstract] [Full Text] [Related]
19. Urine pH in renal calcium stone formers who do and do not increase stone phosphate content with time. Parks JH; Coe FL; Evan AP; Worcester EM Nephrol Dial Transplant; 2009 Jan; 24(1):130-6. PubMed ID: 18662977 [TBL] [Abstract][Full Text] [Related]